[Corrigendum] Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia

• Authors:
  • Xinglin Liang
  • Ruixiang Xia

• View Affiliations

  
  Affiliations: Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
• Published online on: December 13, 2022     https://doi.org/10.3892/or.2022.8463
• Article Number: 26

• Copyright : © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Article

Oncol Rep 47: [Related article:] 18, 2022; DOI: 10.3892/or.2021.8229

Following the publication of the above article, the authors have realized that an error was made during the compilation of Fig. 9, as it appears on p. 10; essentially, the β-actin bands featured in Fig. 9A were inadvertently copied across to Fig. 9B.

Figure 9. Successful transfection of RhoA overexpression plasmid in AML cells. Western blot analysis of (A) KG-1 and (B) Kasumi-1 cells following RhoA overexpression. RhoA and ROCK1 protein expression levels in (C) KG-1 and (D) Kasumi-1 cells following RhoA overexpression. *P<0.05, **P<0.01. RhoA, ras homolog family member A; AML, acute myeloid leukemia; ROCK1, Rho associated coiled-coil containing protein kinase 1; NC, negative control; KIF2A, kinesin family member 2A; si, small interfering.

The revised version of Fig. 9, now showing the correct β-actin bands for Fig. 9B, is shown on the next page. All the authors approve of the publication of this corrigendum, and the authors are grateful to the Editor of Oncology Reports for granting them the opportunity to publish this. The authors regret their oversight in allowing this error to be included in the published paper, and apologize to the readership for any inconvenience caused.